Cargando…

Solid-Phase C1q/C3d Fixing Readouts Correlate with High Median Fluorescence Intensity (MFI) De Novo Donor-Specific HLA Antibodies and C4d(+) Antibody-Mediated Rejection in Kidney Transplant Recipients

BACKGROUND: Solid-phase assays to investigate the complement-activating capacity of HLA antibodies have been utilized to optimize organ allocation and improve transplant outcomes. The clinical utility of C1q/C3d-binding characteristics of de novo donor-specific anti-HLA antibodies (dnDSA) associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Tatapudi, Vasishta S., Kopchaliiska, Dessislava, da Gente, Gilberto J., Buenaventura, Owen F., Singh, Manpreet, Laszik, Zoltan, Adey, Deborah B., Rajalingam, Raja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647455/
https://www.ncbi.nlm.nih.gov/pubmed/34848674
http://dx.doi.org/10.12659/AOT.934175
Descripción
Sumario:BACKGROUND: Solid-phase assays to investigate the complement-activating capacity of HLA antibodies have been utilized to optimize organ allocation and improve transplant outcomes. The clinical utility of C1q/C3d-binding characteristics of de novo donor-specific anti-HLA antibodies (dnDSA) associated with C4d-positive antibody-mediated rejection (C4d(+) AMR) in kidney transplants (KTx) has not been defined. MATERIAL/METHODS: Sera from 120 KTx recipients that had dnDSA concurrent with protocol/cause biopsy (median 3.8 years after transplantation) were screened for C1q and C3d-binding dnDSA. The difference in the incidence of C4d(+) AMR between recipients with and without C1q/C3d-binding dnDSA was assessed. RESULTS: Over 86% of dnDSAs were class II antibodies. The immunodominant dnDSAs characterized by the highest median fluorescence intensity (MFI) in most recipients were HLA-DQ antibodies (67%). Most recipients (62%, n=74) had either C1q(+) (56%), C3d(+) (48%), or both C1q(+)C3d(+) (41.2%) dnDSA, while the remaining 38% were negative for both C1q and C3d. Of those with C1q(+)/C3d(+) dnDSA, 87% had high-MFI IgG (MFI=14144±5363 and 13932±5278, respectively), while 65% of C1q(−)C3d(−) dnDSA had low-MFI IgG (MFI=5970±3347). The incidence of C4d(+) AMR was significantly higher in recipients with C1q(+) (66%), C3d(+) (74%), and C1q(+)C3d(+) (72%) dnDSA than in those with C1q(−)C3d(−) dnDSA (30%) recipients. Recipients with C3d(+)/C1q(+) dnDSA had higher C4d(+) scores on biopsy. CONCLUSIONS: C1q(+)/C3d(+) dnDSA were associated with C4d(+) AMR and high-IgG MFI. Our data call into question the predictive utility of C1q/C3d-binding assays in identifying KTx recipients at risk of allograft failure. In conclusion, IgG MFI is sufficient for clinical management, and the C1q/C3d-assays with added cost do not provide any additional information.